Amir Hossein Aalami1, Hossein Abdeahad2, Ali Shoghi3, Mohammad Mesgari4, Amir Amirabadi5,6, Amirhossein Sahebkar7,8,9,10. 1. Department of Biology, Mashhad Branch, Islamic Azad University, Mashhad, Iran. 2. Department of Nutrition and Integrative Physiology, University of Utah, Salt Lake City, UT USA. 3. Neurosurgery Department, Kermanshah University of Medical Sciences, Kermanshah, Iran. 4. Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Mashhad Iran. 5. Department of Internal Medicine, Mashhad Medical Sciences Branch, Islamic Azad University, Mashhad, Iran. 6. Solid Tumors Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. 7. Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. 8. Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran. 9. School of Medicine, The University of Western Australia, Perth, Australia. 10. School of Pharmacy, University of Medical Sciences, Mashhad, Iran.
Abstract
PURPOSE: Brain tumors (BT) are among the most prevalent cancers in recent years. Various studies have examined the diagnostic role of microRNAs in different diseases; however, their diagnostic role in BT has not been comprehensively investigated. This meta-analysis was performed to assess microRNAs in the blood of patients with BTs accurately. METHODS: Twenty-six eligible studies were included for analysis. The pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), area under curve (AUC), Q*index, summary receiver-operating characteristic (SROC) were assessed using the Meta-Disc V.1.4 and Comprehensive Meta-Analysis V.3.3 software. RESULTS: The diagnostic accuracy of microRNA was high in identifying BT based on the pooled sensitivity 0.82 (95%CI: 0.816-0.84), specificity 0.82 (95%CI: 0.817-0.84), PLR 5.101 (95%CI: 3.99-6.51), NLR 0.187 (95%CI: 0.149-0.236), DOR 34.07 (95%CI: 22.56-51.43) as well as AUC (0.92), and Q*-index (0.86). Subgroup analyses were performed for sample types (serum/plasma), reference genes (RNU6, miR-39, and miR-24), and region to determine the diagnostic power of microRNAs in the diagnosis of BT using pooled sensitivity, specificity, PLR, NLR, AUC, and DOR. CONCLUSION: This meta-analysis suggested that circulating microRNAs might be potential markers for noninvasive early detection of BT.
PURPOSE: Brain tumors (BT) are among the most prevalent cancers in recent years. Various studies have examined the diagnostic role of microRNAs in different diseases; however, their diagnostic role in BT has not been comprehensively investigated. This meta-analysis was performed to assess microRNAs in the blood of patients with BTs accurately. METHODS: Twenty-six eligible studies were included for analysis. The pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), area under curve (AUC), Q*index, summary receiver-operating characteristic (SROC) were assessed using the Meta-Disc V.1.4 and Comprehensive Meta-Analysis V.3.3 software. RESULTS: The diagnostic accuracy of microRNA was high in identifying BT based on the pooled sensitivity 0.82 (95%CI: 0.816-0.84), specificity 0.82 (95%CI: 0.817-0.84), PLR 5.101 (95%CI: 3.99-6.51), NLR 0.187 (95%CI: 0.149-0.236), DOR 34.07 (95%CI: 22.56-51.43) as well as AUC (0.92), and Q*-index (0.86). Subgroup analyses were performed for sample types (serum/plasma), reference genes (RNU6, miR-39, and miR-24), and region to determine the diagnostic power of microRNAs in the diagnosis of BT using pooled sensitivity, specificity, PLR, NLR, AUC, and DOR. CONCLUSION: This meta-analysis suggested that circulating microRNAs might be potential markers for noninvasive early detection of BT.